Oruka Therapeutics, Inc. (ORKA) - What Are Brokerages Thinking About This Stock?

Key Points

• Analysts remain broadly positive: Oruka Therapeutics has a “Moderate Buy” consensus from 11 brokerages, with 10 buys and one sell. The average 12-month price target is $133, ranging from recent targets of $120 to $200.
• Institutional ownership is substantial: Hedge funds and other institutions own 56.44% of the company, with BlackRock establishing a new stake worth approximately $475 million during the second quarter.
• Shares have risen sharply, but the company remains unprofitable: ORKA opened at $96.87, compared with a 1-year range of $25.23 to $115.51. The company reported a quarterly loss of $0.55 per share, missing estimates by $0.04, and insiders have sold about $14.1 million in stock over the past 90 days.

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $133.00.

A number of research analysts recently issued reports on the stock. Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, September 3rd. BTIG Research reiterated a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday, October 19th. Wall Street Zen downgraded Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Piper Sandler reiterated an "overweight" rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Finally, Guggenheim restated a "buy" rating and issued a $200.00 target price on shares of Oruka Therapeutics in a research note on Monday, October 26th.

Insider Activity

In other news, CEO Lawrence Klein sold 75,000 shares of the firm's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the completion of the sale, the chief executive officer owned 925,580 shares in the company, valued at approximately $84,996,011.40. This trade represents a 7.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the company's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the completion of the sale, the insider directly owned 31,771 shares of the company's stock, valued at $2,935,004.98. This trade represents a 20.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 154,950 shares of company stock worth $14,102,680. Insiders own 23.49% of the company's stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently added to or reduced their stakes in ORKA. BlackRock Inc. acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $474,916,000. Remedium Capital Partners LLC boosted its stake in shares of Oruka Therapeutics by 0.9% during the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company's stock worth $76,796,000 after buying an additional 13,247 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of Oruka Therapeutics in the 2nd quarter worth approximately $130,968,000. Avidity Partners Management LP lifted its position in Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company's stock valued at $37,299,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Candriam S.C.A. boosted its holdings in shares of Oruka Therapeutics by 2.6% in the first quarter. Candriam S.C.A. now owns 411,006 shares of the company's stock worth $20,160,000 after buying an additional 10,497 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA opened at $96.87 on Monday. Oruka Therapeutics has a 1-year low of $25.23 and a 1-year high of $115.51. The stock has a market cap of $6.41 billion, a PE ratio of -47.72 and a beta of -0.34. The stock's fifty day simple moving average is $88.47 and its two-hundred day simple moving average is $68.90.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, sell-side analysts forecast that Oruka Therapeutics will post -2.42 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka's pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.